LEENO Industrial (058470) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
14 Jul, 2026Executive summary
Revenue for the first nine months of 2025 reached KRW 287.8 billion, up from KRW 278.2 billion year-over-year, with operating income at KRW 136.6 billion and net income at KRW 112.4 billion.
The company maintains a strong export focus, with 80% of sales from overseas, primarily in semiconductor test sockets and probes.
Major investment in new factory construction is underway to expand production and R&D capabilities, with KRW 39.6 billion already spent out of a planned KRW 97.2 billion.
Financial highlights
Gross margin for the period was 52.3%, with operating margin at 47.5% and net margin at 39.1%.
Cash and cash equivalents increased to KRW 90.7 billion from KRW 54.8 billion at the previous year-end.
No borrowings; debt-to-equity ratio remains at 0%.
Dividend payout ratio maintained at approximately 40%, with a cash dividend of KRW 3,000 per share.
Outlook and guidance
The company expects continued growth in semiconductor and medical device markets, supported by global trends in AI, cloud, and healthcare.
Plans to maintain a dividend payout ratio of around 30% of net income, subject to business performance.
Latest events from LEENO Industrial
- Global semiconductor test leader with strong financials, innovation, and major tech clients.058470
Investor presentation - H1 2026 net income reached KRW 106.32 billion on KRW 242.96 billion revenue, with zero debt.058470
Q2 2026 - Q1 2025 delivered strong profits, robust exports, and a debt-free position, with major facility investment.058470
Q1 2025 - Revenue and profit rose, margins remained high, and major expansion was funded internally.058470
Q4 2024 - H1 2025 net income was KRW 70.5B on KRW 190.9B revenue, with zero debt and robust exports.058470
Q2 2025 - H1 2024 net income margin exceeded 40% on ₩125.8B sales, with zero debt and strong exports.058470
Q2 2024 - Revenue and profit surged on strong semiconductor and medical device demand, with zero debt.058470
Q4 2025 - 2024 Q3 YTD revenue and profit fell, but zero debt and robust R&D support future growth.058470
Q3 2024 - Q1 2026 delivered robust growth, high profitability, and zero debt, with strong export sales.058470
Q1 2026